{"id":"W4400950647","doi":"10.1007/s40120-024-00647-0","title":"Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)","year":2024,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"Biogen","keywords":"Natalizumab; Medicine; Dosing; Crossover study; Clinical endpoint; Randomized controlled trial; Anesthesia; Internal medicine; Placebo","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005322117,0.0001736897,0.0002156086,0.0000754189,0.0001202102,0.00003034448,0.00003534249,0.000121156,0.00005253065],"category_scores_gemma":[0.00001700615,0.0001180992,0.00004416675,0.00009734286,0.0001197185,0.00005511937,0.00001054598,0.0002090508,0.000005123148],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000008963107,"about_ca_system_score_gemma":0.0001376309,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001838841,"about_ca_topic_score_gemma":0.00001902894,"domain_scores_codex":[0.9990008,0.00005304654,0.0001878015,0.0004101306,0.0001355276,0.0002126849],"domain_scores_gemma":[0.9994637,0.0001403149,0.00004495503,0.0001851147,0.00005408848,0.0001117666],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4010312,0.01323847,0.001283961,0.000170151,0.001207763,0.01217432,0.002845465,0.00002233504,0.007559082,0.0006126267,0.0008700765,0.5589846],"study_design_scores_gemma":[0.0755033,0.8125735,0.01127762,0.0003201135,0.001681924,0.009685453,0.0004664663,0.003689656,0.007809051,0.0006752631,0.07530423,0.001013432],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930821,0.004278628,0.0000466924,0.0005612115,0.0007074301,0.001023007,0.00003652762,0.0001084753,0.0001559491],"genre_scores_gemma":[0.9984652,0.0007201874,0.00001921314,0.0005027091,0.0001059058,0.00004916296,0.00005360571,0.00002661214,0.00005744832],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.799335,"threshold_uncertainty_score":0.4815948,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06544853152701602,"score_gpt":0.3220524910896717,"score_spread":0.2566039595626556,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}